利用β细胞功能模型描述1期和2期1型糖尿病的代谢表型
研究在TrialNet站点筛查的1期(30例)和2期(27例)1型糖尿病患者中,采用5点2小时口服葡萄糖耐量试验及标准指标与口服最小模型评估β细胞功能。标准胰岛素分泌与敏感性指标在两组间无差异,而口服最小模型显示2期患者胰岛素分泌(P<.001)和敏感性(P=.034)更低、胰岛素清除增加(P=.006)。较高的基线φ总与疾病进展风险降低相关(OR 0.92 [0.86, 0.98],P=.016),独立于分期。
要点
- 标准胰岛素分泌与敏感性指标未能区分1期与2期1型糖尿病。
- 口服最小模型显示2期患者胰岛素分泌(P<.001)和敏感性(P=.034)更低、清除增加(P=.006)。
- 较高基线φ总与进展风险降低相关(OR 0.92 [0.86, 0.98],P=.016),独立于分期。
核心结论
- 口服最小模型可描述1期与2期1型糖尿病的差异代谢表型,并识别φ总为进展预测因子,支持其作为1型糖尿病预防试验的敏感工具和终点。
研究设计与样本
- 研究纳入在TrialNet站点筛查的1型糖尿病胰岛自身免疫个体,无血糖异常者为1期(30例),有血糖异常者为2期(27例),均接受5点2小时口服葡萄糖耐量试验。
- 采用标准胰岛素分泌指标(曲线下面积、C肽、稳态模型评估2-B)和敏感性指标(稳态模型评估胰岛素抵抗、稳态模型评估2-S、Matsuda指数)以及口服最小模型衍生的胰岛素分泌(φ总)、敏感性(敏感性指数)和清除率来刻画队列。
主要发现
- 标准胰岛素分泌和敏感性指标在1期与2期1型糖尿病之间无差异。
- 口服最小模型显示2期1型糖尿病患者的胰岛素分泌低于1期(P<.001)。
- 口服最小模型显示2期1型糖尿病患者的胰岛素敏感性低于1期(P=.034)。
- 口服最小模型显示2期1型糖尿病患者的胰岛素清除率高于1期(P=.006)。
- 较高的基线φ总与疾病进展风险降低相关,独立于分期(OR 0.92 [0.86, 0.98],P=.016)。
临床怎么用
- 作者认为口服最小模型可作为1型糖尿病预防试验的敏感工具和终点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staging preclinical type 1 diabetes (T1D) and monitoring the response to disease-modifying treatments rely on the oral glucose tolerance test (OGTT). However, it is unknown whether OGTT-derived measures of beta cell function can detect subtle changes in metabolic phenotype, thus limiting their usability as endpoints in prevention trials. OBJECTIVE: To describe the metabolic phenotype of people with Stage 1 and Stage 2 T1D using metabolic modelling of β cell function. METHODS: We characterized the metabolic phenotype of individuals with islet autoimmunity in the absence (Stage 1) or presence (Stage 2) of dysglycemia. Participants were screened at a TrialNet site and underwent a 5-point, 2-hour OGTT. Standard measures of insulin secretion (area under the curve, C-peptide, Homeostatic Model Assessment [HOMA] 2-B) and sensitivity (HOMA Insulin Resistance, HOMA2-S, Matsuda Index) and oral minimal model-derived insulin secretion (φ total), sensitivity (sensitivity index), and clearance were adopted to characterize the cohort. RESULTS: Thirty participants with Stage 1 and 27 with Stage 2T1D were selected. Standard metrics of insulin secretion and sensitivity did not differ between Stage 1 and Stage 2 T1D, while the oral minimal model revealed lower insulin secretion (P < .001) and sensitivity (P = .034) in those with Stage 2 T1D, as well as increased insulin clearance (P = .006). A higher baseline φ total was associated with reduced odds of disease progression, independent of stage (OR 0.92 [0.86, 0.98], P = .016). CONCLUSION: The oral minimal model describes the differential metabolic phenotype of Stage 1 and Stage 2 T1D and identifies the φ total as a progression predictor. This supports its use as a sensitive tool and endpoint for T1D prevention trials.
引用
- Galderisi A, Bonet J, Ismail HM, et al. Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function. J Clin Endocrinol Metab. 2025. PMID: 39992257. doi:10.1210/clinem/dgaf086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。